Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis
Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. We conducted a retrospective case-series stud...
Gespeichert in:
Veröffentlicht in: | Clinical gastroenterology and hepatology 2021-04, Vol.19 (4), p.816-824 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 824 |
---|---|
container_issue | 4 |
container_start_page | 816 |
container_title | Clinical gastroenterology and hepatology |
container_volume | 19 |
creator | Abdelfatah, Mohamed M. Noll, Alan Kapil, Neil Shah, Rushikesh Li, Lianyong Nustas, Rosemary Li, Baiwen Luo, Hui Chen, Huimin Xia, Liang Mekaroonkamol, Parit Shahnavaz, Nikrad Keilin, Steven Willingham, Field Christie, Jennifer Cai, Qiang |
description | Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis.
We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months).
At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052).
In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% |
doi_str_mv | 10.1016/j.cgh.2020.05.039 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2406947180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S154235652030700X</els_id><sourcerecordid>2406947180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</originalsourceid><addsrcrecordid>eNp9kEFLwzAYhoMobk5_gBfp0UtrkiZtgyeROYXBPMybELLk68xom5pkwv69HZs7evnyEd73ge9B6JbgjGBSPGwyvf7KKKY4wzzDuThDY8IZTcuSsPPjnvOCj9BVCBuMqWCivESjnDKO84KN0efcdes0gm-TxTZq10Li6mSmQvRWJ-_g04VXTTLtjAva9fu_XeO8a3cuDiOxXbL0oGILXTw1Xa88BBuu0UWtmgA3x3eCPl6my-fXdL6YvT0_zVOdiyKmudIFLTkYQznjrCQANZRARKH5ylRFVVMCBGNFdF2RUiimtVArBianlTIin6D7A7f37nsLIcrWBg1Nozpw2yApw4UYuBUeouQQ1d6F4KGWvbet8jtJsNxLlRs5SJV7qRJzOUgdOndH_HbVgjk1_iwOgcdDAIYjfyx4GbSFToOxHnSUxtl_8L98FIh3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406947180</pqid></control><display><type>article</type><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</creator><creatorcontrib>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</creatorcontrib><description>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis.
We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months).
At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052).
In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2020.05.039</identifier><identifier>PMID: 32450364</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Diabetes ; Gastric Emptying ; Psychologic ; Therapy</subject><ispartof>Clinical gastroenterology and hepatology, 2021-04, Vol.19 (4), p.816-824</ispartof><rights>2021 AGA Institute</rights><rights>Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</citedby><cites>FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</cites><orcidid>0000-0002-9931-5410 ; 0000-0003-0830-4634 ; 0000-0002-7071-3001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2020.05.039$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32450364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdelfatah, Mohamed M.</creatorcontrib><creatorcontrib>Noll, Alan</creatorcontrib><creatorcontrib>Kapil, Neil</creatorcontrib><creatorcontrib>Shah, Rushikesh</creatorcontrib><creatorcontrib>Li, Lianyong</creatorcontrib><creatorcontrib>Nustas, Rosemary</creatorcontrib><creatorcontrib>Li, Baiwen</creatorcontrib><creatorcontrib>Luo, Hui</creatorcontrib><creatorcontrib>Chen, Huimin</creatorcontrib><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Mekaroonkamol, Parit</creatorcontrib><creatorcontrib>Shahnavaz, Nikrad</creatorcontrib><creatorcontrib>Keilin, Steven</creatorcontrib><creatorcontrib>Willingham, Field</creatorcontrib><creatorcontrib>Christie, Jennifer</creatorcontrib><creatorcontrib>Cai, Qiang</creatorcontrib><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis.
We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months).
At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052).
In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</description><subject>Diabetes</subject><subject>Gastric Emptying</subject><subject>Psychologic</subject><subject>Therapy</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLwzAYhoMobk5_gBfp0UtrkiZtgyeROYXBPMybELLk68xom5pkwv69HZs7evnyEd73ge9B6JbgjGBSPGwyvf7KKKY4wzzDuThDY8IZTcuSsPPjnvOCj9BVCBuMqWCivESjnDKO84KN0efcdes0gm-TxTZq10Li6mSmQvRWJ-_g04VXTTLtjAva9fu_XeO8a3cuDiOxXbL0oGILXTw1Xa88BBuu0UWtmgA3x3eCPl6my-fXdL6YvT0_zVOdiyKmudIFLTkYQznjrCQANZRARKH5ylRFVVMCBGNFdF2RUiimtVArBianlTIin6D7A7f37nsLIcrWBg1Nozpw2yApw4UYuBUeouQQ1d6F4KGWvbet8jtJsNxLlRs5SJV7qRJzOUgdOndH_HbVgjk1_iwOgcdDAIYjfyx4GbSFToOxHnSUxtl_8L98FIh3</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Abdelfatah, Mohamed M.</creator><creator>Noll, Alan</creator><creator>Kapil, Neil</creator><creator>Shah, Rushikesh</creator><creator>Li, Lianyong</creator><creator>Nustas, Rosemary</creator><creator>Li, Baiwen</creator><creator>Luo, Hui</creator><creator>Chen, Huimin</creator><creator>Xia, Liang</creator><creator>Mekaroonkamol, Parit</creator><creator>Shahnavaz, Nikrad</creator><creator>Keilin, Steven</creator><creator>Willingham, Field</creator><creator>Christie, Jennifer</creator><creator>Cai, Qiang</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9931-5410</orcidid><orcidid>https://orcid.org/0000-0003-0830-4634</orcidid><orcidid>https://orcid.org/0000-0002-7071-3001</orcidid></search><sort><creationdate>202104</creationdate><title>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</title><author>Abdelfatah, Mohamed M. ; Noll, Alan ; Kapil, Neil ; Shah, Rushikesh ; Li, Lianyong ; Nustas, Rosemary ; Li, Baiwen ; Luo, Hui ; Chen, Huimin ; Xia, Liang ; Mekaroonkamol, Parit ; Shahnavaz, Nikrad ; Keilin, Steven ; Willingham, Field ; Christie, Jennifer ; Cai, Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-3ac6275edd2545471eefe7e196c5bd868f21e100a1cf8179a4cc9ab4ed328ad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Diabetes</topic><topic>Gastric Emptying</topic><topic>Psychologic</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelfatah, Mohamed M.</creatorcontrib><creatorcontrib>Noll, Alan</creatorcontrib><creatorcontrib>Kapil, Neil</creatorcontrib><creatorcontrib>Shah, Rushikesh</creatorcontrib><creatorcontrib>Li, Lianyong</creatorcontrib><creatorcontrib>Nustas, Rosemary</creatorcontrib><creatorcontrib>Li, Baiwen</creatorcontrib><creatorcontrib>Luo, Hui</creatorcontrib><creatorcontrib>Chen, Huimin</creatorcontrib><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Mekaroonkamol, Parit</creatorcontrib><creatorcontrib>Shahnavaz, Nikrad</creatorcontrib><creatorcontrib>Keilin, Steven</creatorcontrib><creatorcontrib>Willingham, Field</creatorcontrib><creatorcontrib>Christie, Jennifer</creatorcontrib><creatorcontrib>Cai, Qiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelfatah, Mohamed M.</au><au>Noll, Alan</au><au>Kapil, Neil</au><au>Shah, Rushikesh</au><au>Li, Lianyong</au><au>Nustas, Rosemary</au><au>Li, Baiwen</au><au>Luo, Hui</au><au>Chen, Huimin</au><au>Xia, Liang</au><au>Mekaroonkamol, Parit</au><au>Shahnavaz, Nikrad</au><au>Keilin, Steven</au><au>Willingham, Field</au><au>Christie, Jennifer</au><au>Cai, Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>19</volume><issue>4</issue><spage>816</spage><epage>824</epage><pages>816-824</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis.
We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months).
At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04–1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022–1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110–1.008; P = .052).
In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32450364</pmid><doi>10.1016/j.cgh.2020.05.039</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9931-5410</orcidid><orcidid>https://orcid.org/0000-0003-0830-4634</orcidid><orcidid>https://orcid.org/0000-0002-7071-3001</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1542-3565 |
ispartof | Clinical gastroenterology and hepatology, 2021-04, Vol.19 (4), p.816-824 |
issn | 1542-3565 1542-7714 |
language | eng |
recordid | cdi_proquest_miscellaneous_2406947180 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
subjects | Diabetes Gastric Emptying Psychologic Therapy |
title | Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A46%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20Outcome%20of%20Gastric%20Per-Oral%20Endoscopic%20Pyloromyotomy%20in%20Treatment%20of%20Gastroparesis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Abdelfatah,%20Mohamed%20M.&rft.date=2021-04&rft.volume=19&rft.issue=4&rft.spage=816&rft.epage=824&rft.pages=816-824&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2020.05.039&rft_dat=%3Cproquest_cross%3E2406947180%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406947180&rft_id=info:pmid/32450364&rft_els_id=S154235652030700X&rfr_iscdi=true |